Hypertension and Vascular
Disease Models

Validated Models and In Vivo Pharmacology Studies for Drug Development

Back to Pharmacology and Toxicology Assessment top page

Advancing Therapies for Hypertension and Vascular Diseases

Hypertension and vascular disease affect over 1.2 billion people globally, contributing to serious complications like heart attack and stroke. Despite existing therapies, many patients remain at high cardiovascular risk, and the growing prevalence driven by aging and lifestyle factors increases the global health burden. The complexity of these conditions, including dysfunction in vascular regulation and constriction of blood vessels, underscores the need for personalized treatments, improved safety, and preventive strategies. Continued innovation in methods for studying disease mechanisms and drug effects is essential to enhance patient outcomes and reduce healthcare costs.

As a leading preclinical discovery research organization, Inotiv supports drug discovery with in vivo studies and disease models that replicate key characteristics of hypertension and vascular disease. These models help researchers assess cardiac function, identify pharmacological targets, and evaluate the efficacy and safety of new compounds. Our scientists collaborate with clients to design tailored studies that align with specific research goals and ensure comprehensive test methodologies for evaluating potential therapeutics.

In Vivo Models of Hypertension and Vascular Diseases

HYPERTENSIVE HEART DISEASE MODELS

Hypertensive heart disease involves structural and functional changes in the left ventricle, left atrium, and coronary arteries due to chronic high blood pressure. Increased left ventricular afterload leads to myocardial hypertrophy, which can progress to heart failure and increased mortality. It is classified by the presence or absence of heart failure and may result in diastolic, systolic, or combined heart failure. Patients face higher risks of acute complications, including decompensated heart failure, acute coronary syndrome, and sudden cardiac death.

Key Models

Angiotensin II-Induced Hypertension Mouse Model
Dahl-Salt Sensitive (DSS) Rat Model
DOCA + Salt-Induced Hypertension Rat Model
Spontaneously Hypertensive Rat Model

PULMONARY ARTERIAL HYPERTENSION (PAH) MODELS

PAH is a progressive and uncommon lung disorder where blood pressure rises in the pulmonary arteries. The condition occurs when pulmonary small arteries narrow and thicken, limiting blood flow and increasing pressure in the vascular system. This puts additional strain on the right ventricle of the heart, forcing it to work harder to push blood through the lung arteries, which can eventually compromise its ability to maintain proper blood circulation across the body. This can also and cause right ventricular remodeling, leading to right-side heart failure.

Key Models

Monocrotaline-Induced PAH Rat Model

VASCULAR LEAK MODELS

Vascular leakage, also known as capillary leak syndrome or vascular leak syndrome (VLS), occurs when blood plasma escapes through capillary walls into surrounding tissues, organs, or body cavities. It is a hallmark of many critical illnesses, including sepsis, acute respiratory distress syndrome, and severe trauma. Vascular leakage is a leading cause of death among intensive care unit patients.

Key Models

Captopril-Induced Vascular Leak Mouse and Rat Model

Not seeing the in vivo model you need? Explore all our models for Cardiovascular Disease or contact us to discuss creating a new hypertension or vascular disease model. Our dedication to scientific advancement supports the continuous generation of new models and the improvement of existing disease models, providing cutting-edge solutions tailored to your research objectives.

Watch our on-demand webinar, Hypertension, A Driver of Cardiovascular and Renal Disease, where Inotiv scientists explore the role of translational animal models in cardiovascular and renal disease research. The webinar emphasizes hypertension as a key factor in disease progression and highlights how these models are used to develop innovative therapeutics.

Featured speakers include Inotiv’s industry experts Crystal West, PhD (left) and Flavia Machado, PhD (right).

Hypertension-A-Driver-of-Cardiovascular-and-Renal-Disease-speakers

Selected Study Endpoints

For drug discovery and development in hypertension and vascular disease, we provide a broad selection of key endpoints for pharmacology studies. As preclinical discovery research organization, our team partners with clients to design studies that align with their specific research goals, ensuring the selection of the most appropriate endpoints. While the list below highlights some of our capabilities, we offer an extensive range of services and collaborate closely with clients to develop customized solutions that meet their unique study requirements for testing their novel compound.

Systemic blood pressure
Pulmonary arterial pressure
Comprehensive panel of biomarkers
Histology and pathology

Comprehensive Services for Drug Development

We provide a full suite of research services to support every stage of drug development, from early discovery to the critical data required for IND filings. Our integrated approach streamlines the process, enhancing efficiency and effectiveness. With a focus on customized solutions, we deliver robust, translational data to drive successful outcomes. Our expertise in preclinical research ensures rigorous evaluation of drug candidates, providing valuable insights to inform development decisions. Explore our key service areas, each designed to support drug discovery and development with precision and expertise.